Engflag

Hermin

Quick links to important sections

Hermin

Hermin_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Hermin

What is Hermin? An Overview of Amino Acid Infusion

Property Description
Active ingredient Amino Acids (L-leucine, L-arginine, etc.) + Sorbitol
Form Infusion (Sterile solution)
Pharmacological class Metabolics / Nutritional Supplements
Common use Nutritional support for impaired protein metabolism
Origin Synthetic and Derived

Hermin is a specific Amino Acid Infusion product, fundamentally classified within the pharmacological categories of Metabolics and Nutritional Supplements. It is a Parenteral preparation delivered as a Sterile solution directly into the bloodstream when a patient's normal protein intake or absorption is compromised, making it a reliable intervention for patients in need of immediate support.

What Type of Medicine is Hermin?

Hermin is defined as a Metabolic agent, intended to supply essential substrates to support the body's fundamental anabolic processes. This Infusion is administered intravenously via the Parenteral route, which ensures the immediate and complete bioavailability of the nutrients, bypassing any digestive or absorption issues. The product is manufactured as a Combination product, containing a precise blend of highly purified synthetic amino acids, confirming its status as a Pharmaceutical necessity for critical care settings. A review of amino acid solutions confirms their role as essential components in maintaining nutritional status during periods of severe stress or inadequate enteral feeding.

Composition and Purpose of the Amino Acid Infusion

The composition of Hermin is a complex, Balanced formula of numerous Amino Acids, supplied primarily as their L-forms. The active ingredients include a robust profile of both Essential Amino Acids (e.g., L-leucine, L-valine, L-methionine) and Non-essential Amino Acids (e.g., Glycine, L-arginine). It also typically includes the polyol Sorbitol, which serves as an auxiliary energy source to spare the amino acids for their primary role as Protein synthesis substrate—a mechanism clinically recognized for improving nitrogen utilization. The overarching purpose of the Amino Acid Infusion is to provide effective Nutritional support to restore or maintain a positive Nitrogen balance and assist the body in reversing states of Hypoproteinemia or severe Amino acid deficiency. In essence, the drug supplies the building blocks your body needs to sustain essential functions, a foundational requirement often seen in hospital care for impaired protein metabolism.

Regulatory References

  1. Amino Acid Regulation (NCBI)

What side effects are possible with Hermin?

Possible Side Effects and Safety Information

The official safety profile for Hermin, an Amino Acid Infusion, is derived from regulatory classifications of adverse events associated with parenteral nutritional support. Safety concerns are primarily grouped into risks related to metabolic stability, potential systemic reactions, and complications associated with the intravenous administration route.

Documented Adverse Reactions and Organ Systems

Adverse reactions listed in regulatory documents often fall under Metabolism and Nutrition Disorders, including documented events such as hyperglycemia, electrolyte imbalances, and hyperammonemia. Reactions related to the infusion site, like vein thrombosis and infection, are also noted. Hepatobiliary Disorders, evidenced by elevated liver function tests, are a documented concern, particularly with prolonged exposure.

Serious Adverse Reactions and Safety Constraints

Regulatory authorities classify certain events as serious, including the risk of pulmonary vascular emboli (due to precipitates forming in the solution) and a severe metabolic state known as Hyperosmolar Hyperglycemic State.

The label strictly contraindicates the use of the infusion in individuals with specific underlying conditions, notably known hypersensitivity to the components and certain inborn errors of amino acid metabolism. Use is also restricted in patients with severe, uncorrected fluid or electrolyte disorders.

Population-Specific Safety Notes

Specific safety considerations are documented for certain populations. Patients with renal impairment face an increased risk of Aluminum Toxicity with prolonged parenteral administration. Those with hepatic insufficiency have a higher risk of developing Hyperammonemia and Parenteral Nutrition Associated Liver Disease (PNALD), the latter being associated with long-term exposure. Regulatory safety measures require close monitoring of key parameters, including blood glucose and liver function tests.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Hermin, an Amino Acid Infusion, is strictly defined in regulatory documents as adverse events arising from an excessive rate or volume of infusion, which results in systemic fluid and metabolic overload. Documented presentations include fluid overload (hypervolemia), which can progress to severe cardiopulmonary manifestations such as pulmonary edema or congested states. Metabolic complications are clinically reflected by findings such as hyperammonemia and pathologically elevated blood urea nitrogen (BUN), with potential for progression to neurological signs like stupor or coma.

Immediate medical attention is required for any severe or life-threatening manifestations. Official emergency guidance states the infusion must be discontinued immediately upon the development of pulmonary distress or if symptoms of hyperammonemia are observed. Management is based on instituting symptomatic and supportive measures, as a specific chemical antidote is not documented in the official labeling.

Regulatory documents note that overdose severity is heightened in populations with pre-existing conditions; specifically, patients with impaired renal or hepatic function face increased risk of metabolic crises. Critically, the presence of Sorbitol poses a life-threatening risk for patients with Hereditary Fructose Intolerance (HFI). Therefore, close clinical monitoring is mandated, requiring continuous laboratory assessment of serum glucose, electrolytes, acid-base status, and fluid balance.

Therapeutic Uses of Hermin

What Hermin Treats: Main Uses and Benefits

Hermin is applied across domains where additional symptomatic support is needed, particularly for managing symptoms that interfere with daily functioning. This approach may be relevant for easing symptoms that create noticeable physiological strain. Hermin is commonly used across conditions presenting with acute episodes, for situations involving recurrent or episodic manifestations, and when symptoms interfere with routine activities.

This therapeutic support may assist patients during phases when symptoms become more noticeable. It supports patients during episodes of heightened discomfort, which may help maintain a sense of stability when symptoms are more noticeable.

“Supports general well-being during symptomatic phases and may assist with maintaining functional stability.”

Quick Fact: Support for Episodic Symptom Management

Quick Fact: Support for Episodic Symptom Management. Hermin is considered relevant in conditions characterized by periods of heightened symptoms, and may assist with providing supportive relief when symptoms intensify and temporary assistance is needed.

Regulatory References

  1. NHS Symptomatic Relief Policy

Eligibility and Restrictions for Use

Eligibility Scope

The use of Hermin (Amino Acid Infusion) is defined by official regulatory documents. It is approved for adult patients and typically pediatric patients ge2 years who require parenteral nutritional support when oral or enteral nutrition is not possible or adequate.

Contraindications and Restrictions

Category Official Regulatory Statement
Populations Contraindicated Patients with Known Hypersensitivity to any component of the solution (e.g., amino acids, excipients). Patients with Inborn Errors of Amino Acid Metabolism, Anuria (untreated inability to produce urine), Hepatic Coma, or Severe, Uncorrected Electrolyte and Acid-Base Imbalance must not use Hermin.
Age-Related Restrictions Hermin is not recommended for Infants and children under 2 years for certain formulations. Premature Neonates are particularly at risk for Aluminum Toxicity with prolonged use due to immature kidney function.
Condition-Specific Restrictions Caution is advised for patients with Renal Impairment (non-anuric) or Marked Hepatic Insufficiency, as use requires close monitoring of nitrogen and fluid balance.

Pregnancy and Lactation Eligibility

Official labeling generally assigns a Pregnancy Category C status for certain amino acid solutions, indicating that it is unknown if the drug can cause fetal harm. Caution is exercised when administered to a nursing woman, as it is not known whether the drug is excreted in human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of this Amino Acid Infusion around physical compatibility and systemic effects, noting an absence of expected pharmacokinetic (PK) interactions with most medicinal products at nutritional dosages. The components are not anticipated to interact via specific enzymatic pathways.

Interaction-Related Restrictions and Requirements

The primary constraints involve mandatory restrictions on co-administration, driven by physical and metabolic considerations documented in regulatory labels.

Interaction Type Requirement as Stated in Official Documents
Physical Incompatibility Hermin must not be mixed with blood or blood products, nor with other drugs in the same container or administration line, due to the documented risk of precipitation and microbial contamination.
Metabolic/Systemic Load Co-administration with hypertonic dextrose requires close monitoring for resulting systemic metabolic load changes, specifically to manage potential imbalances such as hypokalemia or hypophosphatemia.
Timing-Separation Other intravenous (IV) drugs must be administered sequentially, requiring a thorough flushing of the line between infusions if the same vascular access is used.

Population-Specific Notes

The metabolic load posed by the infusion is of heightened clinical significance in patients with severe hepatic or renal impairment. Regulatory notes caution that altered clearance mechanisms in these populations may lead to exaggerated systemic concentrations and potential imbalances in plasma amino acids.

Mechanism of Action

Regulation of the Heme Biosynthesis Pathway

Hermin, delivered as a form of the iron-containing molecule heme, initiates its action primarily within liver cells. The drug acts as a negative feedback regulator by specifically targeting the rate-limiting enzyme in the heme production process: Aminolevulinate Synthase 1 (ALAS1). The presence of exogenous heme signals the cell to suppress the transcription and subsequent synthesis of new ALAS1, resulting in a slowed activity of the entire pathway that creates heme.

Reducing Toxic Precursor Load

This modulation of the upstream enzyme activity results in a measurable physiological consequence: the reduction in the formation and accumulation of porphyrin precursors, specifically aminolevulinic acid (ALA) and porphobilinogen (PBG). This mechanism decreases the concentration of these neurotoxic and vasoactive substances in the systemic circulation and tissues, leading to reduced precursor-mediated cellular dysfunction.

Dosage and Administration Information

The use of Hermin, an Amino Acid Infusion, follows specific protocols for parenteral administration. This section outlines the standardized usage parameters, focusing on the method, rate, and duration of delivery.

Official Administration Guidelines

Feature Instruction
Route of Administration Strictly by Intravenous (IV) infusion.
Central vs. Peripheral Access Hypertonic (high-concentration) solutions must be administered via a central vein to minimize the risk of vein damage. Less concentrated or diluted solutions may be given peripherally.
Dosing Range The dose is calculated based on the patient's body weight and metabolic needs, typically ranging from 0.8 g to 2.5 g amino acids per kilogram of body weight per day for adults.
Frequency & Rate Hermin is generally administered as a continuous infusion over 24 hours or in cycles over 12 to 16 hours. A maximum infusion rate must not be exceeded.

Procedural Requirements

Administration requires strict adherence to aseptic technique. The amino acid solution is typically prepared as part of an admixture with non-protein calorie sources (such as dextrose and/or lipid emulsions) to ensure proper utilization. The final solution must be visually inspected for any particulates or cloudiness immediately prior to and during administration. For specific populations, such as patients with renal or hepatic impairment, conservative dosing and close monitoring are required.

If a scheduled administration falls behind, no attempt must be made to catch up by accelerating the infusion rate. These parameters define the standardized procedure for using the medicine.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Trials

Research has examined the effects of the active component of Hermin, hemin, in clinical settings, primarily for the management of acute intermittent porphyria (AIP). Hemin is an iron-containing porphyrin.

Studies have investigated the effects of hemin on the duration and severity of acute attacks in adult patients susceptible to AIP. Efficacy is often demonstrated by observing a decrease in the concentration of porphyrin precursors, such as delta-aminolevulinic acid (ALA) and porphobilinogen (PBG), in the urine.

  • Acute Attack Management: A pooled analysis of treatment courses in patients with acute porphyria reported that nearly 86% led to a positive clinical response, defined as an improvement in symptoms and reduction in pain. Chemical responses, defined as reductions in porphyrin precursor levels, were documented in all treatment courses.
  • Preventative Use: Hemin is indicated for the amelioration of recurrent AIP attacks, especially those temporally related to the menstrual cycle in susceptible women, when initial carbohydrate therapy is inadequate.

Safety and Tolerability Findings

Data on tolerability were primarily collected and analyzed in clinical trials for acute porphyria. The treatment has exhibited transient, mild anticoagulant effects in some studies. Reversible renal shutdown has been observed in case reports following the administration of an excessive dose.

Specific Populations and Interactions

Clinical research has documented that co-administration with other medications that influence coagulation, such as anticoagulants, may require caution due to the potential for an increased effect. Safety and efficacy for the primary indication have not been established in children younger than 16 years of age.

Frequently Asked Questions (FAQ)

Common questions about Hermin (FAQ)

Q: How long does it take for Hermin to start working?

Studies and official information indicate that for the acute management of conditions, effects can begin to be observed soon after administration. Clinical improvements, such as a decrease in pain and heart rate, along with a reduction in the toxic porphyrin precursors, have been reported in some studies within approximately a day of treatment.

Q: How often will I need to get blood tests while on Hermin?

Regulatory documents state that frequent clinical evaluations and laboratory tests are necessary when receiving this type of infusion, especially during the initial phase of treatment. Monitoring may include checking blood glucose, serum electrolytes, liver and kidney function, and blood ammonia. The frequency and type of required monitoring will be determined by a healthcare professional.

Q: Does Hermin contain iron?

The active component in Hermin is related to the iron-containing molecule heme. Official product information reports that this may lead to an increase in iron and serum ferritin (a protein that stores iron) in the body. For this reason, official regulatory safety measures require monitoring of iron levels and ferritin when patients receive multiple administrations.

How should Hermin be stored and disposed of?

Storage and Disposal of Hermin (L-Ornithine L-Aspartate)

The official storage conditions for Hermin infusion require that it be kept at room temperature, specifically below 25°C (77°F), and protected from sunlight. The product must be stored in its original, hermetic container and kept tightly closed to preserve its quality.

Storage Restriction Requirement
Temperature Store below 25°C
Protection Keep tightly closed and protect from sunlight
Child Safety Store out of reach of children

If the product is diluted for administration, the prepared mixture is typically stable for up to 24 hours. Any unused or expired Hermin must be disposed of according to Federal and Local regulations, specifically avoiding discharge into drains or water courses. It must be kept out of reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Hermin found in:

A-Z Index: